Connecting the Dots of a Rare Connective Tissue Disease: Pseudoxanthoma Elasticum

Review began 06/23/2021

Review ended 09/21/2021

Published 10/04/2021

© Copyright 2021

Yenior et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Ashley L. Yenior¹, George Pujalte¹, Jeff Nadwodny¹, Lorena C. Costa², Richard J. Presutti¹

1. Department of Family Medicine, Mayo Clinic, Jacksonville, USA 2. College of Medicine, Santa Casa de Misericordia de Vitoria, Vitoria, BRA

Corresponding author: Ashley L. Yenior, yenior.ashley@mayo.edu

Abstract

Pseudoxanthoma elasticum (PXE) is a rare, autosomal recessive connective tissue disease that manifests primarily in the skin, eyes, vasculature, and gastrointestinal tract. Most cases occur in women and are present in the third decade of life. Diagnosis is confirmed via skin biopsy or by genetic testing that reveals a variant *ABCC6* gene. We present the case of a 68-year-old woman who came to the clinic to discuss her daughter's diagnosis of PXE, specifically, what testing she and her family should pursue. A family pedigree revealed a strong family history of abdominal aortic aneurysm (AAA). Although PXE has not been directly related to AAA, this raised concern for familial connective tissue disease. It was recommended that all family members undergo AAA screening with ultrasound, but that not all family members warranted genetic testing. Patients diagnosed with PXE should establish care with specialists to monitor for adverse outcomes.

Categories: Dermatology, Family/General Practice, Genetics

Keywords: family history, genetic counseling, intervention, multidisciplinary, connective tissue disorder, autosomal recessive

Introduction

Pseudoxanthoma elasticum (PXE) is a rare connective tissue disease characterized by dystrophic mineralization of elastic fibers that can affect primarily the skin, eyes, cardiovascular, and gastrointestinal tract [1,2]. It is an autosomal recessive condition with a molecular mutation in the *ABCC6* gene, located on the short arm of chromosome 16 [3]. It demonstrates incomplete penetrance where the estimated incidence is approximately one in 25,000 to 100,000 people, with women accounting for two-thirds of cases [2,4,5]. PXE typically presents as xanthomatous skin lesions, which should indicate a skin biopsy with genetic testing, if needed [1,2].

In this case, a 68-year-old woman discusses her daughter's diagnosis of PXE, specifically, whether she and her family should pursue genetic testing. A family pedigree showed a history of abdominal aortic aneurysm (AAA) in both the patient's and her husband's families. Although PXE has not been directly related to AAA [6], this raised concern for a familial connective tissue disease due to the presence of two well-known heritable disorders that affect the connective tissue in the same family. A multidisciplinary approach and annual monitoring of her relatives were recommended.

Case Presentation

A 68-year-old woman presented to discuss whether genetic testing for her family would be appropriate, since her daughter (age 35) had been recently diagnosed with PXE. The patient's daughter presented to a plastic surgeon with a scalp lesion. Subsequently, a lesion similar to that in Figure 1 was identified on her lateral neck. The lesion was biopsied, and the histopathological results (Figures 2, 3) were consistent with PXE. As seen in Figure 3, the soft tissue becomes mineralized leading to fragmentation of elastic fibers [7]. The mechanism of this change is unknown [7].

How to cite this article

Yenior A L, Pujalte G, Nadwodny J, et al. (October 04, 2021) Connecting the Dots of a Rare Connective Tissue Disease: Pseudoxanthoma Elasticum. Cureus 13(10): e18481. DOI 10.7759/cureus.18481

FIGURE 1: Representative image of xanthomatous skin lesion, a common presentation of PXE

FIGURE 2: Histopathological image of the patient's daughter's xanthomatous lesion, consistent with pseudoxanthoma elasticum

FIGURE 3: A magnified view of the histopathological image in Figure 2, with arrows identifying the fragmented elastic fibers of a pseudoxanthoma elasticum lesion

After careful family history inquiry, a family pedigree (Figure 4) showed a strong history of aneurysms in the patient's and her husband's families. There was no known history of parental consanguinity or Jewish ancestry. She inquired about the next steps for herself, her husband, and their children.

FIGURE 4: Family pedigree

AAA: Abdominal Aneurysm, PXE: Pseudoxanthoma Elasticum

The patient did not have xanthomatous skin findings and denied having angina, claudication, or changes in vision. Since the majority of PXE-related symptoms present in the third decade of life [2], a decision was reached that genetic testing was unnecessary for herself and her husband. The patient's daughter, who has confirmed PXE, established care with an internist, cardiologist, and ophthalmologist. Her other children considered genetic testing for PXE and established care with appropriate specialists to be evaluated for the disease.

It was recommended that all family members undergo AAA screening with ultrasound due to their strong family history, and an echocardiogram was advised to evaluate for an aneurysm. Cardiovascular screening for the patient did not find signs of an aneurysm.

The most common adverse outcome of PXE is macular scarring and hemorrhage that may precede cutaneous signs [2]. This suggests that family members of diagnosed patients should undergo ophthalmologic screening as well. Ophthalmologic screening for the patient was negative.

Discussion

PXE is a multisystem connective tissue disorder that affects elastic fibers, presenting characteristically with skin lesions (typically yellowish papules) generally located on the lateral neck (Figure 1) and flexural surfaces [4], and with ocular involvement (macular scarring, hemorrhage, and angioid streaks of the retina) [1,2]. PXE can also affect multiple organ systems including the cerebrovascular system leading to stroke and transient ischemic attacks [1], the cardiovascular system leading to claudication, angina, and myocardial infarction [2], the renovascular system leading to hypertension [2], and the gastrointestinal system leading to upper gastrointestinal bleeding and mesenteric ischemia [1,2,8].

Dermatologic changes are typically the first presenting symptom and can appear as early as five years old, whereas retinal changes develop later in life but are typically seen on routine eye examinations as early as 10-30 years old [2]. Diagnosis of PXE is therefore challenging as the initial diagnostic cutaneous findings are subtle and diagnosis usually occurs later in life when ocular and vascular complications occur [2,9].

Diagnostic criteria of PXE were first proposed at a Consensus Conference in 1992 and have been updated numerous times, including most recently in 2014 [9]. Definitive PXE can be diagnosed with two pathologic mutations of the *ABCC6* gene or ocular findings in an individual less than 20 years old such as angioid streak or peau d'orange [9]. This criterion must be seen together with characteristic PXE skin changes including papules and plaques on the neck or flexural creases and histologic evidence on skin biopsy including calcified elastic fibers in the dermis with positive calcium stain [9].

An AAA is also a connective tissue disorder associated with the degradation of elastin and collagen fibers. Biochemical and environmental factors are known to be relevant and familial predisposition is well recognized. AAA may occur in isolation or as part of a heritable syndrome [10]. According to the family pedigree, familial AAA occurs in the patient's husband's family, on account of more than one family member is affected. As for the patient's family, it is not possible to confirm if the aneurysm occurrence is heritable or sporadic since only her mother was affected. The relationship between PXE and AAA has not yet been established but is well known that both conditions are heritable connective tissue disorders that can involve alteration in the elastic fibers of the vasculature [2,10].

The diagnosis and management of PXE require a multidisciplinary approach. Recommendations based on expert opinion outline that at the time of diagnosis, patients should undergo a complete skin check, a dilated eye examination, a baseline echocardiogram, a stress test, and a Doppler ultrasound of the peripheral vasculature. Annual monitoring should include an ophthalmic and cardiovascular examination [2].

Due to the genetic inheritance of PXE, it is appropriate to offer genetic counseling for those who are affected, are carriers, or are at risk of being carriers with prenatal or preimplantation genetic testing for pregnancies at increased risk [2]. Pregnant patients with PXE will typically have normal pregnancies as it is not associated with a markedly increase in fetal loss and there is a low incidence of gastrointestinal bleeding and retinal complications [2].

Primary Care Physicians can help manage patients with PXE including ensuring they have appropriate annual screening completed and follow up with specialists and provide lifestyle counseling regarding weight control and smoking cessation to lower their risk of cardiovascular disease. Patients should be counseled to avoid contact sports due to the risk of retinal hemorrhage with head trauma [2]. Medications that may precipitate gastrointestinal bleeding should be avoided [2]. Some studies have investigated the use of magnesium, bisphosphonates, and phosphate binders as treatment of PXE; however, this research has been limited and many have not been shown to have statistical significance. Further larger scale and long-term studies are needed in this potential treatment [11].

Conclusions

PXE is a rare autosomal recessive connective tissue disorder, generally presenting in the third decade of life, that manifests primarily through skin lesions, angioid streaks of the retina, cardiovascular disease (e.g., aneurysms), and gastrointestinal bleeding. Diagnosis can be confirmed by dermatopathology or genetic testing. Affected patients should establish care with specialists to monitor for the aforementioned adverse outcomes. If appropriate precautions are taken and routine monitoring is performed, patients with PXE can live normal lives.

The occurrence of PXE and familial AAA in the same family should raise concern for the presence of familial connective tissue disease. Meanwhile, continued progress in understanding the pathophysiology of PXE may provide novel strategies to counteract this currently intractable condition and to better understand the relationship with other connective tissue disorders. Finally, it is important for Primary Care Physicians to understand the possible evaluation and testing needed for family members if a patient's close relative were

to be diagnosed with PXE.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

We would like to acknowledge Tara Brigham, Vitoria Clifton, Alison Dowdell, Livia Nishi, Dr. Leila Tolaymat, and Dr. Olayemi Sokumbi for their invaluable assistance in preparing this manuscript.

References

1. Plomp AS, Bergen AA, Florijn RJ, Terry SF, Toonstra J, van Dijk MR, de Jong PT: Pseudoxanthoma elasticum: Wide phenotypic variation in homozygotes and no signs in heterozygotes for the c.3775delT mutation in ABCC6. *Genet Med*. 2009, 11:852-8. [10.1097/GIM.0b013e3181c00a96](https://doi.org/10.1097/GIM.0b013e3181c00a96)
2. Terry SF, Uitto J: Pseudoxanthoma Elasticum. *GeneReviews* [Internet]. University of Washington, Seattle, WA; 2020.
3. Laube S, Moss C: Pseudoxanthoma elasticum. *Arch Dis Child*. 2005, 90:754-6. [10.1136/adc.2004.062075](https://doi.org/10.1136/adc.2004.062075)
4. Sasso BM, Cintra ML, de Souza EM: Pseudoxanthoma elasticum. *Autops Case Rep*. 2017, 7:18-21. [10.4322/acr.2017.035](https://doi.org/10.4322/acr.2017.035)
5. Szeri F, Miko A, Navasiolava N, et al.: The pathogenic p.(R391G) ABCC6 displays incomplete penetrance implying the necessity of an interacting partner for the development of pseudoxanthoma elasticum. *MedRxiv*. 2020, 20236489. [10.1101/2020.11.26.20236489](https://doi.org/10.1101/2020.11.26.20236489)
6. Schulz V, Hendig D, Schillinger M, et al.: Analysis of sequence variations in the ABCC6 gene among patients with abdominal aortic aneurysm and pseudoxanthoma elasticum. *J Vasc Res*. 2005, 42:424-32. [10.1159/000087900](https://doi.org/10.1159/000087900)
7. Marconi B, Bobyr I, Campanati A, et al.: Pseudoxanthoma elasticum and skin: clinical manifestations, histopathology, pathomechanism, perspectives of treatment. *Intractable Rare Dis Res*. 2015, 4:113-22. [10.5582/irdr.2015.01014](https://doi.org/10.5582/irdr.2015.01014)
8. Dalle I, Geboes K: Vascular lesions of the gastrointestinal tract. *Acta Gastroenterol Belg*. 2002, 65:213-9.
9. Uitto J, Jiang Q, Váradi A, Bercovitch LG, Terry SF: Pseudoxanthoma elasticum: diagnostic features, classification and treatment options. *Expert Opin Orphan Drugs*. 2014, 2:567-77. [10.1517/21678707.2014.908702](https://doi.org/10.1517/21678707.2014.908702)
10. Kuivaniemi H, Shibamura H, Arthur C, et al.: Familial abdominal aortic aneurysms: collection of 233 multiplex families. *J Vasc Surg*. 2003, 37:340-5. [10.1067/mva.2003.71](https://doi.org/10.1067/mva.2003.71)
11. Luo H, Li Q, Cao Y, Uitto J: Therapeutics development for pseudoxanthoma elasticum and related ectopic mineralization disorders: update 2020. *J Clin Med*. 2020, 10:114. [10.3390/jcm10010114](https://doi.org/10.3390/jcm10010114)